首页> 美国卫生研究院文献>Molecules >Two Ellagic Acids Isolated from Roots of Sanguisorba officinalis L. Promote Hematopoietic Progenitor Cell Proliferation and Megakaryocyte Differentiation
【2h】

Two Ellagic Acids Isolated from Roots of Sanguisorba officinalis L. Promote Hematopoietic Progenitor Cell Proliferation and Megakaryocyte Differentiation

机译:从山茱sorb根中分离得到的两种鞣花酸促进造血祖细胞增殖和巨核细胞分化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Using a bioassay-directed chromatographic separation, two ellagic acids were obtained from the ethyl acetate extract of the roots of Sanguisorba officinalis L. On the basis of chemical and spectroscopic methods, the two ellagic acids were identified as 3,3',4-tri-O-methylellagic acid-4'-O-β-d-xyloside and 3,3',4-tri-O-methylellagic acid. Stimulation of cell proliferation was assayed in hematopoietic progenitor cells using the Cell Counting kit-8 method. The megakaryocyte differentiation was determined in human erythroleukemia (HEL) cells using Giemsa staining and flow cytometry analysis. The ellagic acids significantly stimulated the proliferation of Baf3/Mpl cells. Morphology analysis and megakaryocyte specific-marker CD41 staining confirmed that the ellagic acids induced megakaryocyte differentiation in HEL cells. This is the first time that 3,3',4-tri-O-methylellagic acid or 3,3',4-tri-O-methylellagic acid-4'-O-β-d-xyloside are reported to induce megakaryopoiesis, suggesting a class of small molecules which differ from others non-peptidyl, and appears to have potential for clinical development as a therapeutic agent for patients with blood platelet disorders.
机译:使用生物测定指导的色谱分离法,从山茱sorb根的乙酸乙酯提取物中获得了两种鞣花酸。根据化学和光谱法,这两种鞣花酸被鉴定为3,3',4-tri -O-甲基鞣花酸-4'-O-β-d-木糖苷和3,3',4-三-O-甲基鞣花酸。使用Cell Counting kit-8方法在造血祖细胞中测定细胞增殖的刺激。使用吉姆萨(Giemsa)染色和流式细胞仪分析确定人红白血病(HEL)细胞中的巨核细胞分化。鞣花酸极大地刺激了Baf3 / Mpl细胞的增殖。形态分析和巨核细胞特异性标记CD41染色证实,鞣花酸诱导HEL细胞巨核细胞分化。这是首次报道3,3',4-tri-O-甲基鞣花酸或3,3',4-tri-O-甲基鞣花酸-4'-O-β-d-木糖苷诱导巨核细胞生成,提示了一类与其他非肽基不同的小分子,并且似乎具有作为血小板疾病患者的治疗剂的临床开发潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号